Sixty patients with moderate-to-severe psychiatric illness will be recruited for a trial investigating group .
Patients will be randomized to receive either group bright light therapy alongside treatment as usual or treatment as usual only.
The primary outcome will be changes in sleep timing assessed at 6 weeks postintervention using sleep diaries, actigraphy, and melatonin onset measurements.
Secondary outcomes will include changes in sleep quality, depression, anxiety, fatigue, work and social adjustment, and overall well-being.
Group bright light therapy may be beneficial for improving sleep patterns and psychiatric symptoms in this patient population.
Simplified
INTRODUCTION: Circadian rhythm sleep-wake disturbances appear to be prevalent in psychiatric populations and may maintain and exacerbate psychiatric symptoms. (BLT) is, in addition to exogenous melatonin, the treatment of choice for circadian rhythm disorders like (DSWPD) and has yielded promising results in patients with comorbid psychiatric illness. However, such patients are rarely offered this treatment in outpatient clinics. The aim of this randomised controlled trial is to investigate whether group BLT for psychiatric outpatients is superior to treatment as usual (TAU).
METHODS AND ANALYSIS: 60 patients with moderate-to-severe psychiatric illness who meet the criteria for DSWPD will be recruited from an outpatient psychiatric clinic in Norway. They will be randomised (1:1) to a group-based Sleep School Wake Up! For Circadian (SSWU-C) programme conjointly with TAU or to TAU while on a wait list for SSWU-C. The SSWU-C will be delivered over four biweekly sessions, each lasting 120 min; hence treatment will last 6 weeks. Assessments will be collected at baseline (T1) and after the intervention (T2). The primary outcome will be changes in sleep timing using measures such as sleep diaries, actigraphy and dim light melatonin onset (DLMO) at 6 weeks postintervention. Secondary outcomes include changes in other sleep metrics, symptoms of depression, anxiety, fatigue, problems with work and social adjustment and well-being. Mixed models will be used for data analyses.
ETHICS AND DISSEMINATION: Ethical approval was granted in 2020 by the Regional Ethics Committee in Western Norway (REK 2020/66304). Findings will be published in peer-reviewed journals and be presented at research conferences and in relevant media. The results may document the need for more specific sleep-directed treatments in psychiatric clinics as a way of treating not only circadian rhythm sleep-wake disorders but also as a treatment to alleviate psychiatric symptoms.
TRIAL REGISTRATION NUMBER: NCT05177055.
Key numbers
60 patients
Target Sample Size
Total participants planned for the trial
6 weeks
Duration of Treatment
Length of the intervention period
Full Text
We can’t show the full text here under this license.
Competing interests: AW-L, MG and BB have all written books about sleep which they receive royalties for. MG is the CEO of WINK Sleep which provides courses on the assessment and treatment of sleep disorders. He is also the Head of Sleep Science at Sleep Cycle AB, which provides premium paid subscription to its app sleep tracking capabilities. BB is the CEO of the Bergen Sleep Center and director of the Norwegian Competence Center for Sleep Disorders. IWS was employed at Wonderland Mattresses for a short period in 2022. Both IWS and SP are affiliated with the Norwegian Competence Center for Sleep Disorders. All other authors declare no competing interests.
PubMed
Weekly Circadian Biology Brief
You found one interesting study. We’ll send the next 7.
Get 7 new circadian biology papers each week, explained in plain English with direct links to the originals.
